Press Releases


Therapeutic Solutions International Releases “DermalStilbene” a Topical Formulation of Pterostilbene

OCEANSIDE, Calif., May 21, 2018 (GLOBE NEWSWIRE) — Via OTC PR Wire — Therapeutics Solutions International, Inc., (OTC Markets:TSOI) announced today the availability of a topical form of pterostilbene called “DermalStilbene.”

As previously stated, pterostilbene has been demonstrated in numerous publications to possess therapeutic effects in animal models of numerous inflammatory-associated conditions including cancer, diabetes, and heart failure, but it has also been shown to “protect hairless mice against UVB radiation-induced skin damage and carcinogenesis1“, and “was able to reduce biofilm formation and kill the MRSA in immune cells by virtue of its strong antibacterial activity and facile delivery across biomembranes2

“The release of this new product is meant to complement our other pterostilbene containing products such as ProJuvenol and NanoStilbene, and we are pleased to make this available to our customers for topical application,” said Timothy Dixon, President, and CEO of Therapeutic Solutions International.

“Pterostilbene is a more potent form of resveratrol, which both activate similar molecular pathways including SIRT-1. This protein called a “sirtuin” is known to possess anti-aging effects based on laboratory studies3. While clinical studies have not been performed yet, it is not outside of the realm of possibility that pterostilbene based products may possess a beneficial effect on aging cells,” said Dr. James Veltmeyer, Republican Congressional Candidate and Scientific Advisory Board Member of TSOI.


About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. The Company’s corporate website is and e-commerce at

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.